Journal Information
Vol. 54. Issue 3.
Pages 310-312 (1 March 2001)
Share
Share
Download PDF
More article options
Vol. 54. Issue 3.
Pages 310-312 (1 March 2001)
Full text access
Enfermedad de Gaucher (homozigoto D409H/D409H): evolución con tratamiento enzimático sustitutivo
Gaucher's disease with d409h/d409h genotype. Evolution with enzyme replacement therapy
Visits
9638
F. Castelló Gironaa,
Corresponding author
secrepa@cs.vhebron.es

Correspondencia: Servicio de Pediatría. Hospital Materno-Infantil Vall d'Hebron. P.° Vall d'Hebrón, 119-129. 08035 Barcelona
, C. Domínguez Luengob, M. del Toro Rieraa, A. Chabás Bergonc
a Servicio de Pediatría Hospital Materno-Infantil Vall d'Hebron. Barcelona
b Centro de Investigaciones en Bioquímica i Biología Molecular Hospital Vall d'Hebron. Barcelona
c Instituto de Bioquímica Clínica. Barcelona
This item has received
Article information

La enfermedad de Gaucher se debe a mutaciones en el gen que codifica la glucocerebrosidasa. La mutación D409H es la tercera más frecuente en España y produce un fenotipo particular con apraxia oculomotora y calcificaciones cardiovasculares de presentación tardía. Se comunica un paciente de 4 años de edad, homozigoto para la mutación D409H, que fue díagnosticado a los 45 días de vida y que inició tratamiento enzimático sustitutivo a la edad de 2 meses. Se expone su evolución a los 4 años de tratamiento.

Palabras clave:
Enfermedad de Gaucher
Mutación D409H
Tratamiento enzimático sustitutivo

Gaucher's disease is caused by mutations in the gene encoding glucocerebrosidase. The D409H mutation is the third most frequent mutation in Spain and has been associated with a particular phenotype, including oculomotor apraxia and cardiac valvular calcifications in late childhood. We report a 4-year-old patient, homozygous for the D409H mutation, who was diagnosed with Gaucher's disease at the age of 45 days. Enzyme replacement therapy was started at the age of 2 months. We report the patient's evolution after 4 years of treatment.

Key words:
Gaucher's disease
D409H Mutation
Enzyme replacement therapy
Full text is only aviable in PDF
Bibliografía
[1.]
N.W. Barton, F.S. Furbish, G.J. Murray.
Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.
Proc Natl Acad Sci USA, 87 (1990), pp. 1913-1916
[2.]
A. Erikson, M. Astróin, J.E. Manson.
Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease.
Neuropediatrics, 26 (1995), pp. 203-207
[3.]
A. Tylki-Szymanska, B. Czartoryska.
Enzyme replacement therapy in typo III Gaucher disease.
J Inher Metab Dis, 22 (1999), pp. 203-204
[4.]
A. Chabas, L. Gort, M. Monfort, F. Castelló, M.C. Dominguez, D. Grinberg.
Recurrence of the D409H mutation in Spanish Gaucher disease patients: description of a new homozygous patient and haplotype analysis.
J Med Genet, 35 (1998), pp. 775-777
[5.]
B. Cormand, L.l. Vilageliu, J. Burguera, A. Chabás.
Gaucher disease in Spanish patients: analysis of eight mutations.
Hum Mutat, 5 (1995), pp. 303-309
[6.]
A. Chabás, B. Cormand, S. Balcells.
Neuronopathic and non-neuronopathic presentation Gaucher disease in patients with the third most common mutation (D409H) in Spain.
J Inherit Metab Dis, 19 (1996), pp. 798-800
[7.]
A. Abrahamov, D. Elstein, V. Gross-Tsur.
Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype.
Lancet, 346 (1995), pp. 1000-1003
[8.]
E. Vyama, M. Uchino, H. Ida.
D409H/D409H genotype in Gaucher-like disease.
J Med Genet, 34 (1997), pp. 175-177
[9.]
A. Chabás, B. Cormand, D. Grinberg.
Unusual expression of Gaucher's disease; cardiovascular calcifications in three sibs homozygous for the D409H mutation.
J Med Genet, 32 (1995), pp. 740-742
[10.]
C.E.M. Hollak, S. Van Weely, M.H.J. Van Oers, J.M.F.G. Cherts.
Marked elevations of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
J Clin Invest, 93 (1994), pp. 1288-1292
[11.]
E. Young, C. Chatterton, A. Vellodi, B. Winchester.
Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with algucerase.
J Inher Metab Dis, 20 (1997), pp. 595-602
[12.]
T. Cox, R. Lachmann, C. Hollak.
Novel oral treatment of Gaucher's disease with N-Butyldeoxynojirimycin (OGT918) to decrease substrate biosynthesis.
Lancet, 355 (2000), pp. 1481-1485
Copyright © 2001. Asociación Española de Pediatría
Download PDF
Idiomas
Anales de Pediatría (English Edition)
Article options
Tools